Cost effectiveness of early metformin in addition to usual care in the reduction of gestational diabetes mellitus effects ( <scp>EMERGE</scp> )—A randomised placebo‐controlled clinical trial
We do not find definitive evidence that early initiation of metformin in addition to usual care for GDM was more cost-effective than usual care alone. The clinical and economic evidence may be considered equivocal, but worthy of further examination.
Authors
- R Mahon
- Alberto Alvarez‐Iglesias (ORCID: https://orcid.org/0000-0001-5011-9008)
- Paddy Gillespie (ORCID: https://orcid.org/0000-0001-6297-9478)
- Declan Devane (ORCID: https://orcid.org/0000-0002-9393-7075)
- Fidelma Dunne (ORCID: https://orcid.org/0000-0003-3682-9403)
- Andrew Smyth (ORCID: https://orcid.org/0000-0002-3320-8292)
- Paula O’Shea (ORCID: https://orcid.org/0000-0001-9392-1711)
- Aoife M. Egan (ORCID: https://orcid.org/0000-0003-0379-9279)
- Martin O’Donnell (ORCID: https://orcid.org/0000-0002-7347-7761)
- John Ferguson (ORCID: https://orcid.org/0000-0001-8475-398X)
- C. Newman (ORCID: https://orcid.org/0000-0002-6712-3668)
Institutions
- Mayo Clinic (US)
- Ollscoil na Gaillimhe – University of Galway (IE)
Publication Details
- Journal
- Diabetic Medicine
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1111/dme.70036
- Primary Topic
- Gestational Diabetes Research and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Research Board